Zacks Research Weighs in on Henry Schein, Inc.’s FY2024 Earnings (NASDAQ:HSIC)

Henry Schein, Inc. (NASDAQ:HSIC) – Research analysts at Zacks Research upped their FY2024 earnings per share (EPS) estimates for Henry Schein in a report issued on Tuesday, April 16th. Zacks Research analyst U. Biswas now anticipates that the company will post earnings of $5.04 per share for the year, up from their prior forecast of $5.03. The consensus estimate for Henry Schein’s current full-year earnings is $5.07 per share. Zacks Research also issued estimates for Henry Schein’s Q4 2025 earnings at $1.37 EPS and FY2025 earnings at $5.38 EPS.

Henry Schein (NASDAQ:HSIC) last issued its earnings results on Tuesday, February 27th. The company reported $0.66 EPS for the quarter, missing analysts’ consensus estimates of $0.70 by ($0.04). Henry Schein had a net margin of 3.37% and a return on equity of 14.03%. The firm had revenue of $3.02 billion during the quarter, compared to analysts’ expectations of $3 billion. During the same quarter last year, the firm earned $1.21 EPS. The business’s revenue for the quarter was down 10.5% compared to the same quarter last year.

Other analysts have also recently issued research reports about the company. Leerink Partnrs reaffirmed a “market perform” rating on shares of Henry Schein in a research report on Monday, February 26th. TheStreet raised Henry Schein from a “c+” rating to a “b-” rating in a research report on Monday, February 26th. JPMorgan Chase & Co. boosted their price objective on Henry Schein from $82.00 to $88.00 and gave the stock an “overweight” rating in a research report on Wednesday, March 6th. Piper Sandler boosted their price objective on Henry Schein from $78.00 to $86.00 and gave the stock an “overweight” rating in a research report on Monday, February 26th. Finally, Evercore ISI boosted their price objective on Henry Schein from $79.00 to $83.00 and gave the stock an “in-line” rating in a research report on Wednesday, February 28th. One investment analyst has rated the stock with a sell rating, six have given a hold rating and five have given a buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $81.09.

Henry Schein Price Performance

Shares of NASDAQ:HSIC opened at $70.20 on Wednesday. Henry Schein has a fifty-two week low of $60.01 and a fifty-two week high of $85.39. The business has a 50-day moving average of $74.53 and a two-hundred day moving average of $72.50. The stock has a market capitalization of $9.02 billion, a P/E ratio of 22.29, a P/E/G ratio of 1.75 and a beta of 0.87. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.67 and a quick ratio of 1.00.

Insider Activity

In other news, CEO Bradford C. Connett sold 6,430 shares of the company’s stock in a transaction that occurred on Wednesday, March 20th. The stock was sold at an average price of $74.28, for a total value of $477,620.40. Following the sale, the chief executive officer now directly owns 73,108 shares in the company, valued at approximately $5,430,462.24. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. In related news, CEO Bradford C. Connett sold 6,430 shares of the stock in a transaction that occurred on Wednesday, March 20th. The stock was sold at an average price of $74.28, for a total transaction of $477,620.40. Following the sale, the chief executive officer now directly owns 73,108 shares in the company, valued at approximately $5,430,462.24. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Vice Chairman James P. Breslawski sold 2,907 shares of the stock in a transaction that occurred on Monday, March 18th. The stock was sold at an average price of $74.37, for a total value of $216,193.59. Following the sale, the insider now owns 209,562 shares in the company, valued at $15,585,125.94. The disclosure for this sale can be found here. Corporate insiders own 1.14% of the company’s stock.

Institutional Investors Weigh In On Henry Schein

A number of large investors have recently bought and sold shares of the business. Cambridge Investment Research Advisors Inc. lifted its holdings in Henry Schein by 2.4% during the 1st quarter. Cambridge Investment Research Advisors Inc. now owns 5,262 shares of the company’s stock worth $459,000 after buying an additional 122 shares in the last quarter. HighTower Advisors LLC raised its stake in Henry Schein by 18.9% during the 1st quarter. HighTower Advisors LLC now owns 14,030 shares of the company’s stock worth $1,220,000 after buying an additional 2,226 shares during the period. MetLife Investment Management LLC raised its stake in Henry Schein by 23.2% during the 1st quarter. MetLife Investment Management LLC now owns 37,733 shares of the company’s stock worth $3,290,000 after buying an additional 7,095 shares during the period. Commonwealth of Pennsylvania Public School Empls Retrmt SYS raised its stake in Henry Schein by 6.6% during the 1st quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 18,555 shares of the company’s stock worth $1,618,000 after buying an additional 1,149 shares during the period. Finally, Dimensional Fund Advisors LP increased its holdings in Henry Schein by 4.1% during the 1st quarter. Dimensional Fund Advisors LP now owns 1,300,357 shares of the company’s stock worth $113,386,000 after purchasing an additional 51,106 shares in the last quarter. 96.62% of the stock is currently owned by institutional investors.

About Henry Schein

Henry Schein, Inc provides health care products and services to dental practitioners and laboratories, physician practices, ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.